Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Cytokine Release Syndrome 1

Interventions

Dexamethasone 32Cyclophosphamide 30fludarabine phosphate 25Melphalan 25Busulfan 25Bortezomib 21Tacrolimus 20Lenalidomide 19Peripheral Blood Stem Cell Transplantation 18Mycophenolic Acid 17Whole-Body Irradiation 16Antilymphocyte Serum 16fludarabine 14Calcium Dobesilate 13Thalidomide 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Methotrexate 10pomalidomide 9Cyclosporine 8Radiotherapy 6Etoposide 6Cord Blood Stem Cell Transplantation 6Surveys and Questionnaires 5Stem Cell Transplantation 5Rituximab 5Methylprednisolone 5sargramostim 4carfilzomib 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Plasma Cell × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT00635154 2018-06-07

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Mayo Clinic

Phase 2 Completed
55 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡